Literature DB >> 34272226

Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation.

Lisa Bero1, Rosa Lawrence2, Louis Leslie2, Kellia Chiu3, Sally McDonald3, Matthew J Page4, Quinn Grundy5, Lisa Parker6, Stephanie Boughton7, Jamie J Kirkham8, Robin Featherstone7.   

Abstract

OBJECTIVE: To compare results reporting and the presence of spin in COVID-19 study preprints with their finalised journal publications.
DESIGN: Cross-sectional study.
SETTING: International medical literature. PARTICIPANTS: Preprints and final journal publications of 67 interventional and observational studies of COVID-19 treatment or prevention from the Cochrane COVID-19 Study Register published between 1 March 2020 and 30 October 2020. MAIN OUTCOME MEASURES: Study characteristics and discrepancies in (1) results reporting (number of outcomes, outcome descriptor, measure, metric, assessment time point, data reported, reported statistical significance of result, type of statistical analysis, subgroup analyses (if any), whether outcome was identified as primary or secondary) and (2) spin (reporting practices that distort the interpretation of results so they are viewed more favourably).
RESULTS: Of 67 included studies, 23 (34%) had no discrepancies in results reporting between preprints and journal publications. Fifteen (22%) studies had at least one outcome that was included in the journal publication, but not the preprint; eight (12%) had at least one outcome that was reported in the preprint only. For outcomes that were reported in both preprints and journals, common discrepancies were differences in numerical values and statistical significance, additional statistical tests and subgroup analyses and longer follow-up times for outcome assessment in journal publications.At least one instance of spin occurred in both preprints and journals in 23/67 (34%) studies, the preprint only in 5 (7%), and the journal publications only in 2 (3%). Spin was removed between the preprint and journal publication in 5/67 (7%) studies; but added in 1/67 (1%) study.
CONCLUSIONS: The COVID-19 preprints and their subsequent journal publications were largely similar in reporting of study characteristics, outcomes and spin. All COVID-19 studies published as preprints and journal publications should be critically evaluated for discrepancies and spin. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ethics (see Medical Ethics); public health; qualitative research

Year:  2021        PMID: 34272226     DOI: 10.1136/bmjopen-2021-051821

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


  4 in total

1.  Correction: Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review.

Authors:  Ariel Izcovich; Martín Alberto Ragusa; Fernando Tortosa; María Andrea Lavena Marzio; Camila Agnoletti; Agustín Bengolea; Agustina Ceirano; Federico Espinosa; Ezequiel Saavedra; Verónica Sanguine; Alfredo Tassara; Candelaria Cid; Hugo Norberto Catalano; Arnav Agarwal; Farid Foroutan; Gabriel Rada
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

2.  Reliability of citations of medRxiv preprints in articles published on COVID-19 in the world leading medical journals.

Authors:  Jean-Francois Gehanno; Julien Grosjean; Stefan J Darmoni; Laetitia Rollin
Journal:  PLoS One       Date:  2022-08-10       Impact factor: 3.752

3.  Transparency and reporting characteristics of COVID-19 randomized controlled trials.

Authors:  Philipp Kapp; Laura Esmail; Lina Ghosn; Philippe Ravaud; Isabelle Boutron
Journal:  BMC Med       Date:  2022-09-26       Impact factor: 11.150

4.  Tracking changes between preprint posting and journal publication during a pandemic.

Authors:  Liam Brierley; Federico Nanni; Jessica K Polka; Gautam Dey; Máté Pálfy; Nicholas Fraser; Jonathon Alexis Coates
Journal:  PLoS Biol       Date:  2022-02-01       Impact factor: 9.593

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.